Asset Details
Do you wish to reserve the book?
Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects
Do you wish to request the book?
Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects
2024
Overview
Nanoparticle-based drug delivery presents a promising solution in enhancing therapies for neurological diseases, particularly cognitive impairment. These nanoparticles address challenges related to the physicochemical profiles of drugs that hinder their delivery to the central nervous system (CNS). Benefits include improved solubility due to particle size reduction, enhanced drug penetration across the blood-brain barrier (BBB), and sustained release mechanisms suitable for long-term therapy. Successful application of nanoparticle delivery systems requires careful consideration of their characteristics tailored for CNS delivery, encompassing particle size and distribution, surface charge and morphology, loading capacity, and drug release kinetics. Literature review reveals three main types of nanoparticles developed for cognitive function enhancement: polymeric nanoparticles, lipid-based nanoparticles, and metallic or inorganic nanoparticles. Each type and its production methods possess distinct advantages and limitations. Further modifications such as coating agents or ligand conjugation have been explored to enhance their brain cell uptake. Evidence supporting their development shows improved efficacy outcomes, evidenced by enhanced cognitive function assessments, modulation of pro-oxidant markers, and anti-inflammatory activities. Despite these advancements, clinical trials validating the efficacy of nanoparticle systems in treating cognitive defects are lacking. Therefore, these findings underscore the need for researchers to expedite clinical testing to provide robust evidence of the potential of nanoparticle-based drug delivery systems.
Publisher
Dove Medical Press Limited,Taylor & Francis Ltd,Dove Press,Dove,Dove Medical Press
Subject
/ Animals
/ Blood-Brain Barrier - drug effects
/ Blood-Brain Barrier - metabolism
/ Brain
/ Disease
/ Drug Delivery Systems - methods
/ Drugs
/ Humans
/ Kinases
/ Ligands
/ Lipids
/ Nanoparticle Drug Delivery System - chemistry
/ Nanoparticle Drug Delivery System - pharmacokinetics
/ Review
/ Tissues
/ Vehicles
